scholarly journals Comparative Analysis of the Euroimmun CXCL13 Enzyme-Linked Immunosorbent Assay and the ReaScan Lateral Flow Immunoassay for Diagnosis of Lyme Neuroborreliosis

2020 ◽  
Vol 58 (9) ◽  
Author(s):  
Katharina Ziegler ◽  
Anca Rath ◽  
Christoph Schoerner ◽  
Renate Meyer ◽  
Thomas Bertsch ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Roc Curve ◽  
Point Of Care ◽  
Lateral Flow ◽  
Lyme Neuroborreliosis ◽  
Diagnostic Tools ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
European Federation ◽  
Point Of Care Test

ABSTRACT Diagnosis of Lyme neuroborreliosis (LNB) is challenging, as long as Borrelia-specific intrathecal antibodies are not yet detectable. The chemokine CXCL13 is elevated in the cerebrospinal fluid (CSF) of LNB patients. Here, we compared the performances of the Euroimmun CXCL13 enzyme-linked immunosorbent assay (CXCL13 ELISA) and the ReaScan CXCL13 lateral flow immunoassay (CXCL13 LFA), a rapid point-of-care test, to support the diagnosis of LNB. In a dual-center case-control study, CSF samples from 90 patients (34 with definite LNB, 10 with possible LNB, and 46 with other central nervous system [CNS] diseases [non-LNB group]) were analyzed with the CXCL13 ELISA and the CXCL13 LFA. Classification of patients followed the European Federation of Neurological Societies (EFNS) guidelines on LNB. The CXCL13 ELISA detected elevated CXCL13 levels in all patients with definite LNB (median, 1,409 pg/ml) compared to the non-LNB controls (median, 20.7 pg/ml; P < 0.0001), with a sensitivity of 100% and a specificity of 84.8% (cutoff value, 78.6 pg/ml; area under the receiver operating characteristic [ROC] curve, 0.93). Similarly, the CXCL13 LFA yielded elevated CXCL13 levels in 31 patients with definite LNB (median arbitrary value, 223.5) compared to the non-LNB control patients (median arbitrary value, 0; P < 0.0001) and had a sensitivity and specificity of 91.2% and 93.5%, respectively (cutoff arbitrary value, 22.5; area under the ROC curve, 0.94). The correlation between the CXCL13 levels obtained by ELISA and LFA was strong (Spearman correlation coefficient r = 0.89; P < 0.0001). The CXCL13 ELISA and the CXCL13 LFA are comparable diagnostic tools for the detection of CXCL13 in the CSF of patients with definite LNB. The advantage of the CXCL13 LFA is the shorter time to result.

scholarly journals Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care

2020 ◽  
Author(s):  
Amanda Haymond ◽  
Claudius Mueller ◽  
Hannah Steinberg ◽  
K. Alex Hodge ◽  
Caitlin W Lehman ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Best Practice ◽  
Point Of Care ◽  
Neutralization Assay ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antibody Testing ◽  
Roc Curve Analysis ◽  
Viral Neutralization

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), became a pandemic in early 2020. Lateral flow immunoassays for antibody testing have been viewed as a cheap and rapidly deployable method for determining previous infection with SARS-CoV-2; however, these assays have shown unacceptably low sensitivity. We report on nine lateral flow immunoassays currently available and compare their titer sensitivity in serum to a best-practice enzyme-linked immunosorbent assay (ELISA) and viral neutralization assay. For a small group of PCR-positive, we found two lateral flow immunoassay devices with titer sensitivity roughly equal to the ELISA; these devices were positive for all PCR-positive patients harboring SARS-CoV-2 neutralizing antibodies. One of these devices was deployed in Northern Italy to test its sensitivity and specificity in a real-world clinical setting. Using the device with fingerstick blood on a cohort of 27 hospitalized PCR-positive patients and seven hospitalized controls, ROC curve analysis gave AUC values of 0.7646 for IgG. For comparison, this assay was also tested with saliva from the same patient population and showed reduced discrimination between cases and controls with AUC values of 0.6841 for IgG. Furthermore, during viral neutralization testing, one patient was discovered to harbor autoantibodies to ACE2, with implications for how immune responses are profiled. We show here through a proof-of-concept study that these lateral flow devices can be as analytically sensitive as ELISAs and adopted into hospital protocols; however, additional improvements to these devices remain necessary before their clinical deployment.

POINT-OF-CARE TEST FOR C-REACTIVE PROTEIN BY A FLUORESCENCE-BASED LATERAL FLOW IMMUNOASSAY

2014 ◽  
Vol 42 (6) ◽  
pp. 635-645 ◽  
Author(s):  
Yongbin Gu ◽  
Yongliang Yang ◽  
Jing Zhang ◽  
ShengXiang Ge ◽  
Zhanghong Tang ◽  
...  
Keyword(s):  
Point Of Care ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Point Of Care Test

Development of Enzyme linked Immunosorbent Assay and Lateral Flow Immunoassay for the Rapid Detection of Dapsone in Foods

2021 ◽  
Author(s):  
Chuanlai Xu ◽  
xin guo ◽  
lu lin ◽  
Shanshan Song ◽  
aihong wu ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Health ◽  
Immunosorbent Assay ◽  
Food Chain ◽  
Rapid Detection ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Food Animals

The abuse of dapsone (DDS) in food animals could result in its accumulation in humans through the food chain thus endangering human health. A sensitive monoclonal antibody (mAb) against DDS...

Rapid Detection of Shellfish Major Allergen Tropomyosin Using Superparamagnetic Nanoparticle-Based Lateral Flow Immunoassay

2011 ◽  
Vol 311-313 ◽  
pp. 436-445 ◽  
Author(s):  
Liang Shi ◽  
Xi Chang Wang ◽  
Yuan Liu ◽  
Ying Lu
Keyword(s):  
Limit Of Detection ◽  
Point Of Care ◽  
High Specificity ◽  
Major Allergen ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Quantitative Detection ◽  
Point Of Care Test ◽  
Western Blot Method ◽  
Food Species

In this study, a competitive assay format using superparamagnetic nanoparticle-based lateral flow immunoassay (LFIA) was developed for rapid, quantitative detection of shellfish major allergen tropomyosin (Tm). Sartorius CN140 nitrocellulose membrane and 0.05mg/mL Tm immobilized in the test line (T line) were optimized in order to improve the performance of the LFIA system. Calibration curves for Tm under PBS-T diluents and carp muscle extraction diluents were established. Limit of detection (LOD) for Tm calibrated by carp muscle matrix was 12.4ng/mL with a work range of 0.01 to 20μg/mL. According to magnetic signals change with the time of sample flowing on the strip, the qualitative time of the LFIA was about 10min, while the quantitative time of the LFIA was about 25min. 30 food species were detected separately by the LFIA and Western blot method to evaluate the specificity of the LFIA. Overall relative agreement of the two methods was 96.7% (29/30). Moreover, intra- and inter-assay precisions of the LFIA for Tm detection were <10.20% and <12.34%, respectively. The average recovery range in different food matrices was 80.3~111.8%, within a reasonable range. Our data confirmed that the superparamagnetic nanoparticle-based LFIA method developed in this study is rapid, simple, high specificity and capable of quantitative test. Consequently, the LFIA has the potential application in the field of point-of-care test of shellfish major allergen Tm.

scholarly journals Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Liding Zhang ◽  
Xuewei Du ◽  
Ying Su ◽  
Shiqi Niu ◽  
Yanqing Li ◽  
...  
Keyword(s):  
Point Of Care ◽  
Elisa Test ◽  
Lateral Flow ◽  
Lateral Flow Immunoassay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Csf Biomarkers ◽  
Transient Nature ◽  
Prodromal Alzheimer’S Disease ◽  
Csf Levels ◽  
Point Of Care Detection

AbstractAβ42 is one of the most extensively studied blood and Cerebrospinal fluid (CSF) biomarkers for the diagnosis of symptomatic and prodromal Alzheimer’s disease (AD). Because of the heterogeneity and transient nature of Aβ42 oligomers (Aβ42Os), the development of technologies for dynamically detecting changes in the blood or CSF levels of Aβ42 monomers (Aβ42Ms) and Aβ42Os is essential for the accurate diagnosis of AD. The currently commonly used Aβ42 ELISA test kits usually mis-detected the elevated Aβ42Os, leading to incomplete analysis and underestimation of soluble Aβ42, resulting in a comprised performance in AD diagnosis. Herein, we developed a dual-target lateral flow immunoassay (dLFI) using anti-Aβ42 monoclonal antibodies 1F12 and 2C6 for the rapid and point-of-care detection of Aβ42Ms and Aβ42Os in blood samples within 30 min for AD diagnosis. By naked eye observation, the visual detection limit of Aβ42Ms or/and Aβ42Os in dLFI was 154 pg/mL. The test results for dLFI were similar to those observed in the enzyme-linked immunosorbent assay (ELISA). Therefore, this paper-based dLFI provides a practical and rapid method for the on-site detection of two biomarkers in blood or CSF samples without the need for additional expertise or equipment. Graphical Abstract

Electrophoresis Titration Model of a Moving Redox Boundary Chip for a Point-of-Care Test of an Enzyme-Linked Immunosorbent Assay

ACS Sensors ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 126-133 ◽  
Author(s):  
Fan-Zhi Kong ◽  
Sharmin Jahan ◽  
Ran Zhong ◽  
Xin-Yu Cao ◽  
Wen-Lin Li ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Point Of Care ◽  
Enzyme Linked Immunosorbent Assay ◽  
Point Of Care Test ◽  
Redox Boundary
Sign in / Sign up

Export Citation Format

Share Document